SK bioscienceLtd Management

Management Kriterienprüfungen 1/4

SK bioscienceLtd's CEO ist Jae-Yong Ahn, ernannt in Mar 2021, hat eine Amtszeit von 3.17 Jahren. besitzt direkt 0.057% der Aktien des Unternehmens, im Wert von ₩2.47B. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.6 Jahre bzw. 3.4 Jahre.

Wichtige Informationen

Jae-Yong Ahn

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	3.3yrs
Eigentum des Geschäftsführers	0.06%
Durchschnittliche Amtszeit des Managements	1.7yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.5yrs

Jüngste Management Updates

Recent updates

SK bioscienceLtd's (KRX:302440) Weak Earnings May Only Reveal A Part Of The Whole Picture

Mar 23

Geschäftsführer

Jae-Yong Ahn (57 yo)

3.3yrs

Amtszeit

Mr. Jae-Yong Ahn is the Chief Executive Officer and President of SK bioscience Co.,Ltd since March 2021 and served as its Chairman since March 2021. He serves as Executive Officer and Director of VAX Busi...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jae-Yong Ahn	CEO, President & Director	3.3yrs	keine Daten	0.057% ₩ 2.3b
Harry Kleanthous	Executive Vice President of Vaccine R&D Strategy & External Innovation	1.7yrs	keine Daten	keine Daten
Sally Choe	Head of Global Clinical Development & Regulatory Affairs	1.7yrs	keine Daten	keine Daten

1.7yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: A302440Das Führungsteam des Unternehmens gilt nicht als erfahren (1.6 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jae-Yong Ahn	CEO, President & Director	no data	keine Daten	0.057% ₩ 2.3b
Hoon Kim	Executive Director	3.3yrs	keine Daten	0.057% ₩ 2.3b
Kwon Ik-Hwan	Independent Chairman of the Board	3.3yrs	keine Daten	keine Daten
Moon Chang-Jin	Independent Outside Director	3.7yrs	keine Daten	keine Daten
Choi Jeong-Wook	Independent Outside Director	3.7yrs	keine Daten	keine Daten

3.5yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrener Vorstand: A302440Die Vorstandsmitglieder gelten als erfahren (3.4 Jahre durchschnittliche Amtszeit).

SK bioscienceLtd Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Insufficient new directors

SK bioscience Co.,Ltd., Annual General Meeting, Mar 25, 2024

High number of new and inexperienced directors

SK bioscience Announces Executive Appointments

Less than half of directors are independent

Recent updates

Consensus EPS estimates fall by 59%

Insufficient new directors

SK bioscienceLtd's (KRX:302440) Weak Earnings May Only Reveal A Part Of The Whole Picture

Full year 2023 earnings released: EPS: ₩291 (vs ₩1,596 in FY 2022)

SK bioscience Co.,Ltd., Annual General Meeting, Mar 25, 2024

SK Bioscience Obtains Prequalification Certification from the World Health Organization

Consensus revenue estimates fall by 13%

Consensus EPS estimates fall by 12%, revenue upgraded

SK bioscience Co.,Ltd. to Report Q4, 2023 Results on Feb 01, 2024

Price target decreased by 7.5% to ₩56,714

SK bioscience Co.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Consensus revenue estimates increase by 15%

Investor sentiment improves as stock rises 17%

Consensus revenue estimates decrease by 17%

SK bioscience Co.,Ltd. to Report Q2, 2023 Results on Jul 28, 2023

Consensus estimates of losses per share improve by 59%

SK Bioscience and Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate

Price target decreased by 8.2% to ₩59,875

Consensus revenue estimates decrease by 34%

Investor sentiment improves as stock rises 17%

Consensus EPS estimates fall by 12%, revenue upgraded

Consensus revenue estimates fall by 18%

Price target decreased by 13% to ₩75,545

SK bioscience Introduces New Partnership Model to Establish Regional Vaccine Hubs

SK bioscience Co.,Ltd. to Report Q4, 2022 Results on Feb 08, 2023

SK Bioscience Co.,Ltd. Receives Expanded Manufacturing and Marketing Approval from the Korean Ministry of Food and Drug Safety for Nuvaxovid

SK Bioscience Receives Biologics License Application Approval of the Skyzoster™ from the National Pharmaceutical Regulatory Agency in Malaysia

High number of new and inexperienced directors

Price target decreased to ₩103,400

Price target decreased to ₩114,700

SK bioscience Announces Executive Appointments

SK bioscience Co.,Ltd. to Report Q3, 2022 Results on Oct 31, 2022

Price target decreased to ₩124,300

Consensus EPS estimates fall by 11%

Investor sentiment deteriorated over the past week

Now 23% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Now 20% undervalued after recent price drop

Investor sentiment deteriorated over the past week

SK bioscience Receives Post Approval Change Application Approval from the Korean Ministry of Food and Drug Safety for Nuvaxovid™ (NVX-CoV2373) COVID-19 Vaccine

Consensus EPS estimates fall by 11%

Consensus revenue estimates fall by 11%

Price target decreased to ₩151,667

Consensus revenue estimates fall by 10%

Investor sentiment improved over the past week

Price target decreased to ₩167,222

Price target decreased to ₩167,222

Consensus EPS estimates fall by 12%

Investor sentiment deteriorated over the past week

Price target decreased to ₩192,250

Consensus EPS estimates fall by 17%

Price target decreased to ₩216,250

Less than half of directors are independent

Price target decreased to ₩225,714

Investor sentiment deteriorated over the past week

South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine

SK Bioscience and GSK Start Phase 3 Trial of Adjuvanted Covid-19 Vaccine Candidate

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit